Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 3
1985 5
1986 3
1987 2
1988 2
1989 4
1990 4
1991 4
1992 3
1993 1
1994 3
1995 1
1996 5
1997 5
1998 3
1999 6
2000 3
2001 3
2002 4
2003 4
2004 4
2005 2
2006 2
2007 4
2008 3
2009 6
2010 5
2011 5
2012 3
2013 3
2014 7
2015 9
2016 2
2017 9
2018 12
2019 6
2020 9
2021 11
2022 14
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Moskowitz CH, et al. Among authors: viviani s. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. Blood. 2018. PMID: 30266774 Free article. Clinical Trial.
Lessons from the Meningitis Vaccine Project.
LaForce FM, Djingarey M, Viviani S, Preziosi MP. LaForce FM, et al. Among authors: viviani s. Viral Immunol. 2018 Mar;31(2):109-113. doi: 10.1089/vim.2017.0120. Epub 2017 Nov 8. Viral Immunol. 2018. PMID: 29116892 Review.
ABVD in the treatment of Hodgkin's disease.
Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. Bonfante V, et al. Among authors: viviani s. Semin Oncol. 1992 Apr;19(2 Suppl 5):38-44; discussion 44-5. Semin Oncol. 1992. PMID: 1384143 Review.
Vinorelbine: a new promising drug in Hodgkin's disease.
Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Devizzi L, et al. Among authors: viviani s. Leuk Lymphoma. 1996 Aug;22(5-6):409-14. doi: 10.3109/10428199609054778. Leuk Lymphoma. 1996. PMID: 8882953 Review.
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: viviani s. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
180 results